{ "Title": "Synthetic covenant-aware planning study — public financial excerpt", "Company": "Fictional Demo Holdings consolidated reporting group", "Currency": "USD", "Status": "Synthetic demonstration agreement and planning annex. All financial records and attestations were created for this example. No external legal or financial review is claimed.", "Reading this excerpt": "Selected financial facts and results from a local demonstration. This is not the complete underlying record and does not independently establish approval. Retained demonstration results and independently worked reference comparisons are labelled separately. Monetary values are exact USD strings; ratios are stated separately.", "Dates": { "Opening balances": "2026-09-30", "Decision interval": "2026-10-01 through 2026-12-31", "Projected covenant test": "2026-12-31", "Liquidity and new-loan repayment follow-through": "2027-01-31", "Test scope": "One contractual covenant test after all 31 December events. January checks repayment and closing unrestricted cash; it is not a second contractual covenant test." }, "Reviewed synthetic assumptions": { "Opening existing debt (USD)": "18000000.00", "Opening total cash (USD)": "3000000.00", "Restricted cash throughout (USD)": "1000000.00", "Minimum unrestricted closing cash (USD)": "500000.00", "Collection on 2026-11-30 (USD)": "3000000.00", "Quarterly base EBITDA (USD)": [ { "Quarter": "2026Q1", "Basis": "Synthetic historical accounts", "Amount": "1000000.00" }, { "Quarter": "2026Q2", "Basis": "Synthetic historical accounts", "Amount": "1000000.00" }, { "Quarter": "2026Q3", "Basis": "Synthetic historical accounts", "Amount": "1000000.00" }, { "Quarter": "2026Q4", "Basis": "Reviewed synthetic forecast", "Amount": "1000000.00" } ], "Earnings period": "Four discrete calendar quarters in 2026. The projected test replaces 2025Q4 with the reviewed 2026Q4 forecast.", "Included Q3 restructuring expense (USD)": "1200000.00", "Adjustment basis": "Already deducted from historical base EBITDA, with synthetic eligibility support. The permitted adjustment is capped at 25% of positive base EBITDA, rounded down to the nearest cent. Forecast restructuring and future addbacks are outside scope.", "Base EBITDA (USD)": "4000000.00", "Permitted adjustment (USD)": "1000000.00", "Adjusted EBITDA (USD)": "5000000.00", "Maximum cash deduction from debt (USD)": "2000000.00", "Covenant basis": "Net debt is gross debt less unrestricted cash, subject to the cash deduction cap, and cannot be negative. Net leverage is net debt divided by adjusted EBITDA.", "Leverage limit": "3.50", "Ratio presentation": "The exact ratio determines the outcome. Only the displayed ratio is rounded half-up to two decimal places.", "Supplier invoice face value (USD)": "3000000.00", "Permitted supplier settlements": [ { "Payment date": "2026-10-01", "Settlement (USD)": "2900000.00", "Discount (USD)": "100000.00" }, { "Payment date": "2026-11-30", "Settlement (USD)": "2950000.00", "Discount (USD)": "50000.00" }, { "Payment date": "2026-12-31", "Settlement (USD)": "3000000.00", "Discount (USD)": "0.00" } ], "Existing debt service": [ { "Date": "2026-12-31", "Interest (USD)": "180000.00", "Principal repaid (USD)": "0.00" }, { "Date": "2027-01-31", "Interest (USD)": "60000.00", "Principal repaid (USD)": "0.00" } ], "Existing interest through follow-through (USD)": "240000.00", "New borrowing alternatives": [ { "Choice": "No new borrowing", "Principal (USD)": "0.00", "Interest (USD)": "0.00" }, { "Choice": "Borrow and repay the quoted loan", "Principal (USD)": "2000000.00", "Draw date": "2026-10-01", "Repayment date": "2027-01-31", "Interest payments": [ { "Date": "2026-12-31", "Interest (USD)": "30000.00" }, { "Date": "2027-01-31", "Interest (USD)": "10000.00" } ], "Total new interest (USD)": "40000.00" } ], "Cash-flow completeness": "All other flows are explicitly zero. Existing debt service remains in cash projections. New borrowing is fully repaid by 31 January; existing debt remains outstanding.", "Event ordering": "On each event date, apply restriction changes, receipts and draws before operating and supplier payments, interest and principal repayment. Check facility exposure before repayment and unrestricted cash at close. Intraday liquidity is outside scope.", "Selection objective": "Minimize new borrowing interest through repayment less supplier discounts, within the permitted choices, cash floor and projected covenant limit. Fixed existing interest is included in cash and full interest reporting. Loan principal is a cash flow, not an economic benefit.", "Contractual earnings assumption": "The synthetic annex excludes the selected supplier discounts and financing interest from contractual EBITDA. This treatment must not be inferred for real agreements." }, "Retained demonstration results": [ { "Plan": "October borrowing baseline", "Evidence": "Assessment retained from the local synthetic demonstration", "Supplier payment date": "2026-10-01", "Supplier settlement (USD)": "2900000.00", "New borrowing (USD)": "2000000.00", "Supplier discount (USD)": "100000.00", "New borrowing interest through repayment (USD)": "40000.00", "Existing borrowing interest through follow-through (USD)": "240000.00", "Full borrowing interest through follow-through (USD)": "280000.00", "Modeled discount less new interest (USD)": "60000.00", "Full borrowing interest less supplier discount (USD)": "180000.00", "Quarter-end unrestricted cash (USD)": "3890000.00", "Minimum unrestricted cash through follow-through (USD)": "1100000.00", "Quarter-end gross debt (USD)": "20000000.00", "Quarter-end cash deduction (USD)": "2000000.00", "Quarter-end net debt (USD)": "18000000.00", "Adjusted EBITDA (USD)": "5000000.00", "Exact projected net leverage": "18/5 = 3.60", "Displayed projected net leverage": "3.60", "Existing debt remaining at follow-through (USD)": "18000000.00", "New debt remaining at follow-through (USD)": "0.00", "Outcome": "Meets the cash floor but breaches the 3.50 covenant limit" }, { "Plan": "Selected November payment without new borrowing", "Evidence": "Lowest-cost feasible permitted plan retained from the local synthetic demonstration", "Supplier payment date": "2026-11-30", "Supplier settlement (USD)": "2950000.00", "New borrowing (USD)": "0.00", "Supplier discount (USD)": "50000.00", "New borrowing interest through repayment (USD)": "0.00", "Existing borrowing interest through follow-through (USD)": "240000.00", "Full borrowing interest through follow-through (USD)": "240000.00", "Modeled discount less new interest (USD)": "50000.00", "Full borrowing interest less supplier discount (USD)": "190000.00", "Quarter-end unrestricted cash (USD)": "1870000.00", "Minimum unrestricted cash through follow-through (USD)": "1810000.00", "Quarter-end gross debt (USD)": "18000000.00", "Quarter-end cash deduction (USD)": "1870000.00", "Quarter-end net debt (USD)": "16130000.00", "Adjusted EBITDA (USD)": "5000000.00", "Exact projected net leverage": "1613/500 = 3.226", "Displayed projected net leverage": "3.23", "Existing debt remaining at follow-through (USD)": "18000000.00", "New debt remaining at follow-through (USD)": "0.00", "Outcome": "Lowest-cost permitted plan meeting the cash floor and the projected covenant limit" } ], "Decision tradeoff": { "Modeled benefit forgone to meet the covenant (USD)": "10000.00", "Explanation": "The October borrowing baseline offers a larger discount after new interest but breaches the covenant. The selected November plan retains a smaller discount without new borrowing. These amounts are modeled benefits, not realized customer savings or total profit." }, "Independent financial reference comparison": { "Evidence": "All six permitted combinations worked independently from the stated assumptions. These are reference workings, not six additional observed live runs.", "Common assumptions": "Adjusted EBITDA is USD 5,000,000.00; existing interest through 31 January is USD 240,000.00; existing debt remaining is USD 18,000,000.00. Each quoted new loan is repaid on 31 January.", "Combinations": [ { "Payment date": "2026-10-01", "New borrowing (USD)": "0.00", "Modeled discount less new interest (USD)": "100000.00", "Quarter-end unrestricted cash (USD)": "1920000.00", "Minimum unrestricted cash (USD)": "-900000.00", "Exact projected net leverage": "402/125 = 3.216", "Outcome": "Fails liquidity on 1 October; not feasible" }, { "Payment date": "2026-10-01", "New borrowing (USD)": "2000000.00", "Modeled discount less new interest (USD)": "60000.00", "Quarter-end unrestricted cash (USD)": "3890000.00", "Minimum unrestricted cash (USD)": "1100000.00", "Exact projected net leverage": "18/5 = 3.60", "Outcome": "Meets liquidity; breaches the covenant" }, { "Payment date": "2026-11-30", "New borrowing (USD)": "0.00", "Modeled discount less new interest (USD)": "50000.00", "Quarter-end unrestricted cash (USD)": "1870000.00", "Minimum unrestricted cash (USD)": "1810000.00", "Exact projected net leverage": "1613/500 = 3.226", "Outcome": "Lowest-cost feasible permitted plan" }, { "Payment date": "2026-11-30", "New borrowing (USD)": "2000000.00", "Modeled discount less new interest (USD)": "10000.00", "Quarter-end unrestricted cash (USD)": "3840000.00", "Minimum unrestricted cash (USD)": "1770000.00", "Exact projected net leverage": "18/5 = 3.60", "Outcome": "Meets liquidity; breaches the covenant" }, { "Payment date": "2026-12-31", "New borrowing (USD)": "0.00", "Modeled discount less new interest (USD)": "0.00", "Quarter-end unrestricted cash (USD)": "1820000.00", "Minimum unrestricted cash (USD)": "1760000.00", "Exact projected net leverage": "809/250 = 3.236", "Outcome": "Feasible; more expensive than the selected November plan" }, { "Payment date": "2026-12-31", "New borrowing (USD)": "2000000.00", "Modeled discount less new interest (USD)": "-40000.00", "Quarter-end unrestricted cash (USD)": "3790000.00", "Minimum unrestricted cash (USD)": "1720000.00", "Exact projected net leverage": "18/5 = 3.60", "Outcome": "Meets liquidity; breaches the covenant" } ] }, "Observed review controls": [ "Making the Q4 earnings forecast unknown prevented determination and approval.", "A conditional preview using the original forecast showed the October baseline breach without resolving or approving the underlying uncertainty.", "Resolving the forecast required a new review and approval before another approved analysis.", "Changing the underlying covenant assumptions made the previous planning approval stale and prevented new analysis under that stale approval.", "Excluding the restructuring adjustment left no feasible plan among the permitted choices.", "Earlier approved results remained available after later changes, with their original assumptions and approval record.", "Human approval authorized analysis only; it did not execute payments or borrowing." ], "Limitations": [ "This is a locally demonstrated fictional example, not a customer deployment, service commitment or realized savings claim.", "The reviewed forecast is an assumption, not a guarantee. Unknown required facts, unresolved adjustment treatment or nonpositive adjusted EBITDA prevent determination; they do not establish infeasibility.", "Only the stated supplier dates, quoted borrowing alternatives, cash flows and single projected covenant test are covered.", "Intraday liquidity, refinancing, additional covenants, foreign currencies, fees and floating interest rates are outside this example.", "Real agreements, legal interpretation, customer data and production readiness require separate review and qualification.", "This selected public excerpt is not the full retained evidence or an independent reproduction package. Its unsigned manifest checks only the integrity of the public files." ] }